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Cost efectiveness of nusinersen for patients 
with infantile-onset spinal muscular atrophy 
in US
Praveen Thokala1* , Matt Stevenson1, Varun M. Kumar2, Shijie Ren1, Alexandra G. Ellis2 
and Richard H. Chapman3
Abstract 
Background: Patients with infantile-onset spinal muscular atrophy (SMA), a rare, genetic neuromuscular disease, do 
not achieve key motor function milestones (e.g., sitting) and have short life expectancy in the absence of treatment. 
Nusinersen is a disease-modifying therapy for patients with SMA.
Objective: The aim of this study was to estimate the cost-effectiveness of nusinersen compared to best supportive 
care (BSC) in patients diagnosed with infantile-onset SMA in the US.
Methods: A de novo economic model was developed with the following health states: “permanent ventilation”, 
“not sitting”, “sitting”, “walking”, and “death”. Short-term data were sourced from the pivotal clinical trials and studies of 
nusinersen (ENDEAR and SHINE). Motor function milestones achieved at the end of follow-up in the clinical trials were 
assumed to be sustained until death. Mortality risks were based on survival modelling of relevant published Kaplan–
Meier data. Costs, life years (LYs), and quality-adjusted life years (QALYs) were discounted at 3% per annum, and the 
analyses were performed from a US health care sector perspective. Scenario analyses and sensitivity analyses were 
conducted to assess the robustness of the results to key parameters.
Results: In our base-case analysis, nusinersen treatment achieves greater QALYs and more LYs (3.24 and 7.64, respec-
tively) compared with BSC (0.46 QALYs and 2.40 LYs, respectively), resulting in an incremental cost per QALY gained 
of approximately $1,112,000 and an incremental cost per LY gained of $590,000 for nusinersen compared to BSC. The 
incremental cost effectiveness ratios did not fall below $990,000 per QALY gained in scenario and sensitivity analyses. 
Results were most sensitive to the length of survival, background health care costs, and utility in the “not sitting” and 
“sitting” health states.
Conclusions: The estimated incremental cost-effectiveness of nusinersen from a US health care sector perspective 
exceeded traditional cost-effectiveness thresholds. Cost-effectiveness was dependent on assumptions made regard-
ing survival, costs, utilities, and whether the motor function milestones were sustained over lifetime. Given the rela-
tively short-term effectiveness data available for the treatment, a registry to collect long-term data of infantile-onset 
SMA patients is recommended.
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Background
Spinal muscular atrophy (SMA) is a rare, genetic neuro-
muscular disease with the most severe case of infantile-
onset SMA (Type I SMA) afecting infants and young 
children. [1, 2] In the United States (US), SMA incidence 
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is approximately one in 10,000 live births or about 500 
new SMA cases per year, of which infantile-onset SMA 
represents approximately 60% of cases. [3]
Patients with infantile-onset SMA do not achieve key 
motor function milestones (e.g., sitting) and have short 
life-expectancy in the absence of treatment. Historically, 
life expectancy in these infantile-onset SMA patients 
was less than 2 years and many infants eventually require 
permanent ventilation. To maintain mobility and func-
tion as long as possible, multidisciplinary, supportive 
care including respiratory, nutritional, gastrointestinal, 
orthopedic, and other support is needed. [4–6] However, 
supportive care does not modify disease progression and 
patients may be entirely dependent on family members 
and caregivers.
In December 2016, the Food and Drug Administration 
(FDA) approved nusinersen (Spinraza®, Biogen Idec), a 
disease-modifying therapy, for the treatment of SMA. [7] 
It is administered via intrathecal injection (into the luid 
surrounding the spinal cord) with four loading doses (day 
0, day 14, day 28, and day 63) and maintenance doses 
every 4 months thereafter. Nusinersen has been studied 
in patients with or likely to develop SMA [8–10], with 
several studies ongoing [11–14].
here are two clinical trials of nusinersen in infantile-
onset SMA, including a phase II, open-label, dose-esca-
lation study (CS3A) [8] and a randomized controlled 
trial with sham control (ENDEAR). [9] For ENDEAR, an 
interim analysis showed statistical superiority of Ham-
mersmith Infant Neurological Examination-“Methods 
Section” (HINE-2) responders favoring nusinersen and 
the study was subsequently terminated prior to the 
planned 13  month follow up. However, longer-term 
results are available for infants in ENDEAR who enrolled 
in the single-arm open label extension (OLE) study 
SHINE. [15].
he aim of this paper is to present the cost-efectiveness 
of nusinersen for treatment of patients with infantile-
onset SMA in the US. Section two (Methods) describes 
the model structure, key assumptions, input data, and 
analyses. Section three (Results) presents the results of 
base-case, scenario, one-way and probabilistic sensitiv-
ity analyses. Section four (Discussion) highlights the key 
points, model limitations and comparison to other mod-
els. he inal section presents the conclusions.
Methods
A de novo model was developed in Microsoft Oice 
Excel 2016, to estimate the lifetime cost-efectiveness of 
nusinersen compared to best supportive care (BSC) for 
patients with infantile-onset SMA, from the US health 
care sector perspective. Costs, life years (LYs), and qual-
ity-adjusted life years (QALYs) were discounted at 3% per 
annum. A modiied societal perspective scenario analy-
sis was also performed, including patient-centric societal 
costs (i.e., non-medical costs) and productivity gains, 
along with patient QALYs and health care costs. his 
model has also been used in the Institute for Clinical and 
Economic Review (ICER) evaluation of nusinersen and 
onasemnogene abeparvovec-xioi (Zolgensma®, Avexis) 
for SMA. [16] Input was sought from the manufacturers, 
patient groups, health economists and clinical experts 
throughout the model development and analysis phase. 
he structure of the model, assumptions, input data, 
model settings and the type of analyses are described in 
detail in this section.
Model overview
he health states in the model related to three con-
structs: the motor function milestones achieved, need for 
permanent ventilation, and death. he motor function 
milestones included sitting and walking. Other motor 
function milestones such as head control, rolling, crawl-
ing, and standing were not modelled as explicit health 
states, but health beneits associated with such improve-
ments were explored as described in “Health State Utili-
ties Section”. Figure 1 depicts the analytic framework for 
the model.
he model used monthly time cycles to estimate life-
time costs, life years (LYs) and quality adjusted life years 
(QALYs). he model contained two parts: (1) a short-
term phase concordant with clinical study data, and (2) 
a long-term extrapolation model. A brief description 
of each is provided here, with detailed explanations on 
assumptions and data presented in subsequent sections.
Short-term data inputs for nusinersen and BSC were 
derived from the ENDEAR trial and SHINE study. [15, 
22] hese data were used directly in the model to cap-
ture the proportion of the patients in the diferent health 
states at diferent points in time, to allow estimation of 
the costs, LYs, and QALYs for the two strategies within 
the study periods.
he long-term model involved the extrapolation of 
motor function milestones, permanent ventilation, and 
mortality, the latter of which was assumed to be con-
ditional on health states. In the base-case analysis, the 
motor function milestones achieved at the end of follow-
up in the clinical trials were assumed to be sustained until 
death (i.e., patients stayed in the same motor function 
milestone-based health state until death). In addition, 
alternative scenarios were also modeled for nusinersen, 
where a proportion of patients lost milestones.
Transition to the “permanent ventilation” health state 
in the model was only possible for patients who did not 
have any motor function milestones (i.e., those in the 
“not sitting” health state). For these patients, both overall 
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survival (OS) and ventilation-free survival (VFS) were 
modelled. Patients who achieved motor function mile-
stones were not considered to be at risk of transitioning 
to “permanent ventilation”. As such, only OS was mod-
elled for the patients with motor function milestones.
Key assumptions
Several key assumptions were made during the modelling 
phase, as listed below. A comprehensive list of assump-
tions and accompanying rationales is available in Addi-
tional ile 1. Appendix S1.
Data from the trials and studies were used directly 
in the short-term model. Motor-function milestones 
achieved at the end of follow up were sustained until 
death. Only patients in the “not sitting” health state could 
transition to the “permanent ventilation” state. In the 
short-term model for nusinersen, it was assumed that 
the observed proportions of patients who could sit and 
attend follow-up visits was generalisable to all patients 
alive.
In the BSC arm, a partitioned survival modeling 
approach was used at the end of the short-term model 
to estimate transitions to “death” and “permanent venti-
lation” from the “not sitting” health state. In the nusin-
ersen arm, we assumed that patients in the “not sitting” 
health state at the end of the short-term model had the 
same survival as those on “permanent ventilation”. his 
assumption may be favorable to nusinersen given that 
observational data suggest lower mortality for patients 
on permanent ventilation compared to those who were 
unable to sit.
In the clinical trials, patients on nusinersen achieved 
interim milestones such as head control, rolling, crawl-
ing, etc. Given these interim milestones were not 
explicitly captured in our model, additional utility ben-
eits were assumed in the nusinersen arm. An addi-
tional utility beneit of 0.05 and 0.1 was attributed to the 
patients in the “not sitting” and “sitting” health states in 
the nusinersen arm, respectively.
A treatment-stopping rule at 24 months was assumed 
for patients on nusinersen who were in “not sitting” and 
“permanent ventilation” health states.
Model inputs
he model inputs for the short-term data, long-term 
extrapolation, health state utilities, costs, and productiv-
ity gains are presented in the next subsections.
Short-term model
Motor function milestones he data on proportions of 
nusinersen patients achieving motor function milestones 
at diferent time points for the diferent strategies were 
based on the ENDEAR trial [9] and the OLE SHINE study. 
[12] Castro et al. [12] reported the results of the SHINE 
study which presents the proportion of patients achieving 
sitting at diferent time points, as shown in Table 1.
With diferent numbers of patients at risk at these time 
points, we followed a multi-stage process to estimate the 
true proportions of nusinersen patients achieving the 
milestones as described in Additional ile 1. Appendix S2.
No patients in the BSC arm were assumed to achieve 
any motor function milestones at any time points, as the 
trial reported that 0% of the patients in the sham con-
trol group achieved the ability to sit independently dur-
ing assessments at days 183, 302, or 394. We could not 
include longer-term data on this estimate in the BSC arm 
as all sham control patients in ENDEAR [9] switched to 
nusinersen treatment in SHINE. [12].
Fig. 1 Model schematic
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Mortality he proportions of patients alive at diferent 
time points were estimated from the OS data presented 
for each strategy. he OS data for nusinersen were from 
patients who received nusinersen in both ENDEAR [9] 
and SHINE. [12] he OS data for BSC were from patients 
who received sham control in ENDEAR.
Permanent ventilation he VFS rates at diferent time 
points were estimated from the combined VFS data in 
ENDEAR [9] and SHINE, [12] and subtracted from the 
OS data to estimate the proportion of patients receiving 
permanent ventilation for the nusinersen arm. he VFS 
data for BSC were from patients who received sham con-
trol in ENDEAR [9] alone.
Not sitting In the short-term model, the proportion of 
patients in the “not sitting” health state was estimated as 
the complement of the sum of proportions of patients on 
permanent ventilation, patients achieving milestones, and 
patients who died.
Long-term model
Extrapolation of motor function milestones Motor func-
tion milestones in the long-term model were extrapolated 
based on milestone status at the end of the short-term 
model, with a base-case assumption that milestone status 
remained the same until death.
Alternative scenarios were also modeled where it was 
assumed that a proportion (ranging from 10 to 30%) of 
patients in the “sitting” health state lost their motor func-
tion milestones.
Extrapolation of mortality and permanent ventilation At 
the end of the short-term model, patients were in one of 
the following health states: “permanent ventilation,” “not 
sitting,” “sitting,” or “walking.”
hose in the “not sitting” health state in the BSC arm 
could transition either to “permanent ventilation” or 
“death” health states, and we modeled both OS and VFS 
for these patients. For those in the “not sitting” health 
state in the nusinersen arm, we modeled transition to 
only “death” (i.e., not to permanent ventilation). However, 
we included the costs of permanent ventilation in the 
3 months prior to death for those transitioning to death 
from this health state.
he patients in all other health states were not consid-
ered to be at risk of transitioning to “permanent ventila-
tion” and, as such, could only transition to “death”.
he long-term risks of mortality associated with each 
of the health states were modelled by itting survival 
curves to digitized, published Kaplan–Meier (KM) data 
most relevant to each health state. We digitized the KM 
data and reconstructed the individual data using the 
methods described in Guyot et al. [17] We itted diferent 
parametric distributions (exponential, Weibull, gamma, 
Gompertz, log-normal, log-logistic, and generalized 
gamma) to these survival data. We identiied the best it-
ting curves based on a combination of clinical plausibil-
ity, it statistics (Akaike information criteria (AIC) and 
Bayesian information criteria (BIC)), and visual inspec-
tion. For each health state, a single parametric distribu-
tion was selected to calculate the estimated probability of 
death in each cycle.
he survival curves used in the base-case analysis for 
long-term extrapolation are presented in Fig. 2. he tran-
sitions from diferent health states, assumptions, data 
sources, and parametric distributions selected to extrap-
olate survival are presented in Additional ile 1. Appendix 
S3.
In Fig.  2, the OS and VFS curves represent the over-
all survival and ventilation-free survival of the patients 
in the “not sitting” health state in the BSC arm, which 
were assumed to be the same as that of the patients in 
the sham control arm of ENDEAR. he OS curve for BSC 
represents the survival of patients in the “not sitting” 
health state at the end of the short-term model, with a 
mean survival time of 1.55 years. he VFS curve, with a 
mean survival of 0.74  years, is subtracted from the OS 
curve to estimate the proportion of patients in the “per-
manent ventilation” health state that transitioned from 
the “not sitting” health state in each cycle.
he curve “survival on permanent ventilation” repre-
sents the survival of patients in the “permanent venti-
lation” health state at the end of the short-term model, 
with a mean survival of 5.3 years. he survival in the “not 
sitting” health state in the nusinersen arm was assumed 
to be the same as the survival on “permanent ventilation”, 
Table 1 Motor function milestones achieved on nusinersen
Baseline
n = 81
Day 64
n = 70
Day 183
n = 65
Day 302
n = 51
Day 394
n = 48
Day 578
n = 31
Day 698
n = 17
% Achieving independent sitting 
(but not walking)
0 1 5 10 15 29 24
% Achieving walking 0 0 0 0 0 0 0
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to account for the survival beneit in the treatment arms 
for achieving interim milestones such as head control and 
rolling among patients in the “not sitting” health state.
he curve “survival in sitting state” represents the sur-
vival of patients in the “sitting” health state at the end of 
the short-term model, based on the assumption that they 
have the same survival as SMA Type II patients, with a 
mean survival of 29.3 years.
Health state utilities
Patient utilities he utilities used in the base-case analy-
ses were derived from multiple sources and are presented 
in Table  2. he utilities reported by homson et  al [18] 
were from a cross-sectional study of individuals with SMA 
in Europe; investigators collected parent/proxy–assessed 
quality of life using the EuroQol-5 Dimensions (EQ-5D) 
3-level version. he mean utility value for patients with 
Type I SMA in the UK was 0.19 (n = 7); we assumed this 
value was the same for both “permanent ventilation” and 
“not sitting” health states in the BSC arm.
he utility for the “sitting” health state was estimated 
as 0.60 from Tappenden et  al., [19] in the evidence 
review group (ERG) report evaluating the submis-
sion of nusinersen for National Institute for Health 
and Care Excellence (NICE). Tappenden et  al. [19] 
report the utilities elicited from the clinical experts 
who advised the ERG, who were asked to provide plau-
sible utility estimates for the diferent health states; it 
should be noted that these utility estimates were not 
preference-based.
Additional utility beneits in the nusinersen arm were 
assumed for achieving interim milestones such as head 
Fig. 2 Survival curves used in the long-term extrapolation model. BSC best supportive care, OS overall survival, VFS ventilation-free survival.*Survival 
in “not sitting” health state in treatment arm is the same as survival on permanent ventilation
Table 2 Patient utility values for health states
Utility value  
(BSC arm)
Source Utility value  
(nusinersen arm)
Source
Permanent ventilation 0.19 Thomson et al., 2017 [18] 0.19 Thomson et al., 2017 [18]
Not sitting 0.19 0.29 Assumption
Sitting 0.60 Tappenden et al., 2018 [19] 0.65 Assumption
Page 6 of 12Thokala et al. Cost Ef Resour Alloc           (2020) 18:41 
control, rolling, standing, crawling, etc. he propor-
tions of patients achieving these interim milestones 
were not available at diferent time points, so the model 
assumed an additional utility beneit for all patients in 
the “not sitting” and “sitting” health states. his was 
implemented in the model as a utility of 0.29 for the 
“not sitting” health state (i.e., an additional utility of 
0.10 compared with BSC) and a utility of 0.65 for the 
“sitting” health state (i.e., an additional utility of 0.05 
compared with BSC) in the nusinersen arm.
Cost inputs
he costs used in the model include treatment costs, 
administration/monitoring costs, and costs associated 
with being in each health state. All costs were inlated to 
2017 values.
Drug acquisition costs he recommended dosage for 
nusinersen is four loading doses (the irst three load-
ing doses administered at 14  day intervals with the 
fourth loading dose administered 30 days after the third 
dose) and a maintenance dose administered once every 
4 months thereafter. Since nusinersen is administered in 
a hospital setting, mark-ups associated with the treat-
ment were included. Average wholesale price (AWP) was 
used to which a 15% discount was applied, relecting the 
weighted average mark-ups seen for treatments adminis-
tered speciically in a hospital outpatient setting. [21].
Administration and monitoring costs All administration, 
laboratory, and monitoring costs associated with nusin-
ersen are presented in Table 3. It was assumed that 40% of 
the patients receive nusinersen in an inpatient setting and 
accrue the costs of inpatient stay and anesthesia. More 
details about these costs are presented in Additional ile 1. 
Appendix S4.
Health state costs he monthly costs associated with 
the diferent health states are presented in Table  4. he 
health care sector perspective included just the health 
care utilization costs while the non-medical costs were 
also included in the modiied societal perspective.
he health care utilization costs were sourced from 
claims analysis of commercial health plans reported by 
Shieh et al. [24] he costs in the “permanent ventilation” 
health state were estimated as the costs associated with 
permanent ventilation added to the costs of the “not sit-
ting” health state. More details of these health state costs 
are presented in Additional ile 1. Appendix S4.
Annual non-medical costs associated with the diferent 
health states were obtained from a report by the Lewin 
Group, [25] and are summarized in Table 4. More details 
of the non-medical costs are presented in Additional 
ile 1. Appendix S4.
Patient productivity gains Patient productivity gains 
were included in a scenario analysis using the modi-
ied societal perspective. No productivity changes were 
assumed for those in the “permanent ventilation” and “not 
sitting” health states. For other health states, data from 
the Lewin Group report [25] on educational attainment 
for SMA patients were combined with data on income by 
education level in the US from the Bureau of Labor Sta-
tistics [26] to estimate the productivity gains as monthly 
income of $4450, as shown in Additional ile 1. Appendix 
S4. hese productivity gains were estimated from the age 
of 25 years until an age of 67 years which represents the 
age of retirement in the US.
Table 3 Treatment and administration cost inputs
*Wholesale acquisition cost (WAC) as of July 1, 2019
† AWP–15%, where AWP is $150,000 per package as of July 1, 2019
Strategy Administration Package size WAC* per package Estimated net cost 
per  package†
Source
Nusinersen treatment 
cost
Intrathecal injection 2.4 mg/ml (5 ml) $125,000 $127,500 Magellan 2016 [20]; 
Redbook 2018 [21]
Administration cost $1209 Assuming 40% of patients receive nusinersen in inpatient settings Physician fee schedule 
2018; [22] Nationwide 
Children’s Hospital 
[23]
Table 4 Monthly Costs in Diferent Health States
*Used only in the modiied societal perspective analyses
Permanent 
ventilation
Not sitting Sitting Walking
Health care utilization 
costs
$28,218 $25,517 $6357 $2499
Non-medical costs* $964 $964 $964 $0
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Model veriication and validation
Model veriication followed standard practices in the 
ield. All mathematical functions in the model were tested 
to ensure they were consistent with the manuscript (and 
Additional ile 1. Appendix materials). Test analyses with 
speciic input values (e.g., all set to 0, or all set to 1, etc.) 
were conducted to ensure the model was producing ind-
ings consistent with expectations. Further, independent 
modelers tested the mathematical functions in the model 
as well as the speciic inputs and corresponding outputs.
Sensitivity and scenario analyses
One-way sensitivity analyses (OWSA) were performed 
using plausible ranges based on published data and 
expert opinion to identify the key drivers of model out-
comes. Probabilistic sensitivity analysis (PSA) was per-
formed by jointly varying all model parameters, using 
1000 simulation runs. Due to the lack of data, the distri-
butions used for costs and utilities in the PSA were mean 
values ± 20%. As such, the true uncertainty is likely to be 
diferent to that represented in our probabilistic analyses.
We also conducted scenario analyses using a modiied 
societal perspective including non-medical costs, alter-
native utility estimates, alternative health state costs, 
alternative survival estimates, using a 10-year time hori-
zon and using a lower (1.5%) discount rate. We also per-
formed alternative scenario analyses not accounting for 
utility beneits of achieving interim milestones (such 
as head control, rolling, crawling, and standing) and 
another scenario where the patients lose milestones, and 
have lower survival and utility in the “sitting” health state.
Results
he base-case results, results of the PSA, scenario analy-
ses and OWSA are presented from the health care sector 
perspective.
Base‑case results
he breakdown of QALYs, LYs and costs according to 
health state for the diferent strategies are presented in 
Additional ile 1. Appendix S5.
he total lifetime costs associated with nusinersen were 
approximately $3.9 million and were $790,000 for BSC 
(Table  5). Nusinersen produces greater QALYs and LYs 
(3.24 and 7.64, respectively) compared with BSC (0.46 
QALYs and 2.40 LYs). his resulted in an incremental 
cost per QALY gained of approximately $1,112,000 and 
an incremental cost per LY gained of $590,000 for nusin-
ersen compared with BSC.
One‑way sensitivity analyses results
he key drivers of uncertainty included monthly costs 
and utility values for the “sitting” and “not sitting” health 
states (Fig. 3).
Probabilistic sensitivity analyses results
Figure  4 presents the cost-efectiveness clouds from the 
PSA for nusinersen versus BSC. he results of the PSA 
suggest that nusinersen had no likelihood of being cost-
efective at thresholds less than $500,000 per QALY.
Scenario analyses results
A number of scenario analyses were performed to iden-
tify the efect of alternative inputs and assumptions on 
the cost-efectiveness results.
Table  6 presents the results from a scenario analysis 
taking a modiied societal perspective. he incremental 
cost per QALY and incremental cost per LY gained for 
nusinersen compared to BSC in the modiied societal 
perspective were slightly less favorable than those in the 
health care sector perspective. his was because non-
medical costs (which included moving or modifying the 
home and purchasing or modifying a vehicle), provided 
in Table 4, accrue for all the health states (except walking) 
for a lifetime, while patient productivity gains are only for 
patients sitting or walking between ages 25 and 67 years. 
he productivity gains did not ofset the non-medical 
costs for nusinersen, as only around 19% of the patients 
in nusinersen arm were in the “sitting” health state and 
none were in the “walking” health state.
he summary results for the other scenario analy-
ses conducted are presented in Table  7. More detailed 
description of the assumptions behind each of these sce-
nario analyses and detailed results are in Additional ile 1. 
Appendix S6.
Table 5 Base-Case Results for nusinersen versus BSC in the health care sector perspective
BSC best supportive care, LY life-year, QALY quality-adjusted life year
*Costs and cost-efectiveness ratios are rounded to the nearest $1000
Drug treatment  costs* Non‑treatment 
health care  costs*
Total  costs* QALYs LYs Incremental results
Cost/QALY  gained* Cost/LY  gained*
Nusinersen $2,231,000 $1,653,000 $3,884,000 3.24 7.64 $1,112,000 $590,000
BSC $0 $789,000 $789,000 0.46 2.40 – –
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Fig. 3 Tornado diagram for one-way sensitivity analyses of nusinersen versus BSC. QALY quality-adjusted life year. The values in the parenthesis in 
the y-axes represents the lower and upper input, respectively. *Lower input corresponds to higher incremental cost-effectiveness ratio and vice 
versa
Fig. 4 Cost-effectiveness clouds for nusinersen versus BSC
Table 6 Scenario analysis results for nusinersen versus BSC: modiied societal perspective
BSC best supportive care, LY life-year, QALY quality-adjusted life year
*Costs and cost-efectiveness ratios are rounded to the nearest $1000
Total costs* QALYs LYs Incremental results
Cost/QALY gained* Cost/LY gained*
Nusinersen $3,944,000 3.24 7.64 $1,124,000 $596,000
BSC $817,000 0.46 2.40 – –
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Removing utility benefit for achieving interim mile-
stones increased the incremental cost per QALY. 
Assuming lower health state costs resulted in more 
favorable incremental cost per QALY ratios. However, 
assuming lower survival or utilities for “sitting” health 
states resulted in less favorable incremental cost-effec-
tiveness ratios. When both poorer survival and lower 
utilities for the “sitting” health state were used, the 
incremental cost per QALY gained was around $1.4 
million. This suggests that the base-case incremen-
tal cost per QALY is an underestimate if the patients 
achieving “sitting” do not do as well as SMA Type II 
patients.
If a larger proportion of patients in the “sitting” 
health state were to lose their milestones, the incre-
mental cost-effectiveness ratios become less favora-
ble (scenarios #6a-6c in Table  7). The scenario which 
assumed that 30% of the patients in the “sitting” health 
state lose milestones and also assumed lower survival 
and lower utilities for those in the “sitting” health 
state, resulted in an incremental cost per QALY of 
approximately $1.5 million and an incremental cost 
per LY gained of $630,000. Note that this scenario 
still includes the utility benefit for achieving interim 
milestones.
The scenario analyses using a 10  year time horizon 
resulted in an incremental cost per QALY of approxi-
mately $1.5 million as all the benefits for the patients 
in the “sitting” health state are not included. The sce-
nario analyses using a discount rate of 1.5% for both 
costs and QALYs resulted in an in incremental cost per 
QALY of approximately $1 million.
Discussion
Summary
his study represents the irst de novo cost-efectiveness 
model of infantile-onset SMA patients in the US setting. 
he base-case incremental cost-efectiveness results were 
approximately $1.1 million per QALY and $600,000 per 
LY compared with BSC.
he incremental cost efectiveness ratios did not fall 
below $990,000 per QALY gained (or $520,000 per LY 
gained) in any of the analyses undertaken. he results 
were most sensitive to the length of survival, the costs 
associated with treating people with SMA, and the utili-
ties in both the “sitting” and “not sitting” health states. 
Results from the probabilistic sensitivity analyses found 
that nusinersen had a zero likelihood of achieving a cost-
efective ratio of less than $500,000 per QALY gained.
Comparison to other models
A recently published manufacturer-funded model com-
pared nusinersen to best supportive care in early-onset 
(Type I) SMA patients in Sweden. he cost-utility model 
was developed from a societal perspective, with a health 
care perspective analysis undertaken as a scenario, using 
a 40  year time horizon. [27] hat model structure was 
also similar to the manufacturer-submitted models to 
NICE, CADTH, and other HTA agencies, with changes 
mainly to the patient utilities used and costs to match 
the respective jurisdiction. In our model, the incremental 
cost-efectiveness ratio was approximately $1.1 million 
per QALY while the corresponding results were substan-
tially more favorable in the manufacturer-funded model, 
at approximately SEK 5.6 million ($623,000) per QALY.
Table 7 Scenario Analyses for nusinersen versus BSC
LY life-year, QALY quality-adjusted life year
*Costs and cost-efectiveness ratios are rounded to the nearest $1000
Cost per QALY* Cost per LY*
Base-case results $1,112,000 $590,000
Scenario #1: Assuming no utility benefits for interim milestones $1,303,000 $590,000
Scenario #2: Assuming lower monthly health state costs of $10,434 and $13,135 for “not sitting” and “perma-
nent ventilation” health states, respectively
$990,000 $525,000
Scenario #3: Assuming lower utility of 0.5 for “sitting” health state $1,265,000 $590,000
Scenario #4: Assuming lower survival (mean survival of 15.6 years) for “sitting” health state $1,253,000 $624,000
Scenario #5: Assuming lower utility of 0.5 and lower survival (mean 15.6 years) for “sitting” health state $1,407,000 $624,000
Scenario #6a: Assuming 10% in “sitting” health state lose milestone at end of short-term model $1,143,000 $593,000
Scenario #6b: Assuming 20% in “Sitting” Health State Lose Milestone at End of Short-Term Model $1,178,000 $597,000
Scenario #6c: Assuming 30% in “sitting” health state lose milestone at end of short-term model $1,218,000 $601,000
Scenario 7: Scenario assuming 30% in “sitting” health state lose milestone at end of short-term model, lower 
utilities and survival for “sitting” health state
$1,509,000 $630,000
Scenario #8: Using a 10 year time horizon $1,460,000 $700,000
Scenario #9: Using 1.5% discount rate for both costs and QALYs $1,052,000 $566,000
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his diference is primarily due to the more favorable 
assumption in the manufacturer-funded model of poten-
tially continuous improvement with nusinersen beyond 
the trial duration. Both models employed health states 
based on motor function milestones, but beyond the 
trial period, our model assumed patients remained in the 
same health state as at end of trial, whereas in the man-
ufacturer-funded model, it was assumed that patients 
receiving nusinersen could only improve or remain sta-
ble in each cycle, while patients in the BSC arm could not 
improve over time but could only worsen or stay within 
the same health state. his assumption of continuous 
improvement with nusinersen beyond the trial duration 
in the manufacturer-funded model was also questioned 
by the independent ERG and noted by the appraisal com-
mittee in the NICE appraisal. [28].
Limitations
Our analyses have important limitations. Most of these 
relate to the lack of availability of robust data and the 
assumptions required to overcome this. here is no long-
term follow-up, resulting in considerable uncertainty 
related to the prognosis of patients with SMA. We used 
motor function milestones to deine broad health states 
and had to assume relationships between these motor 
function milestone-based health states and survival. 
Uncertainty in long-term survival was partially accounted 
for in sensitivity and scenario analyses. As there are no 
long-term data on the extrapolation of motor function 
milestones, the base-case analyses assume that these are 
sustained until death. Given nusinersen is a lifelong treat-
ment it is possible that some patients may achieve fur-
ther milestones in the longer term. On the other hand, 
it is possible that the patients may lose the milestones 
achieved. As such, in the absence of long-term follow-up 
data for nusinersen, the base-case analyses assume that 
these are sustained until death. However, as reported in 
Table 7, we performed scenario analyses assuming a pro-
portion of the patients in the “sitting” health state lose 
their milestones to account for the possibility of deterio-
rating treatment efect over time. Given the lack of long-
term follow up of treatment efectiveness and utility data, 
a registry of SMA patients is recommended.
Furthermore, some relevant interim motor function 
milestones (such as head control, crawling, rolling) were 
not included in the model. Given patients on nusinersen 
also achieved interim milestones, the base-case analyses 
included a utility beneit for patients receiving nusinersen 
compared to those receiving BSC to make allowances for 
better functioning in nusinersen arm within these broad 
health states. However, we also performed scenario 
analysis excluding this utility beneit associated with the 
interim milestones (please see Scenario 1 in Table 7).
We could not estimate disease progression parameters 
(e.g., transition probabilities) without access to individual 
patient data from the studies. As such, the data for the 
diferent strategies during the study period were used 
directly in the model to estimate short-term costs and 
QALYs. his is subject to limitations, especially towards 
the end of the follow up period, where censoring has 
reduced the relatively small numbers recruited in the 
studies.
Robust utility data were lacking, with many identi-
ied studies lacking face validity. As such, we used util-
ity data derived from several sources that were believed 
to be coherent. he base-case analyses were comple-
mented with sensitivity and scenario analyses to explore 
the uncertainty in these values. Similarly, cost data were 
lacking, requiring several assumptions to be made. hese 
uncertainties were partially addressed through altering 
the cost inputs in sensitivity analyses, as well as present-
ing threshold-based price ranges. However, due to the 
lack of data, the distributions used for costs and utili-
ties in the PSA are mean values ± 20%. As such, the true 
uncertainty is likely to be diferent than that represented 
in our probabilistic analyses.
Given the nature of SMA, it is di cult to disentangle 
the adverse events due to treatment from the compli-
cations associated with SMA itself, which are already 
accounted for in the health state costs and disutilities. As 
such, the costs and disutilities of adverse events were not 
included in the model.
Finally, our analyses using a modiied societal perspec-
tive did not include quality of life burden associated with 
caregivers, as the methods for performing economic 
evaluations including such caregiver burden are still 
under development. Incorporating caregiver burden may 
lead to counterintuitive results due to prolonged negative 
productivity efects and unknown quality of life efects on 
caregivers when children who need substantial care live 
longer. Furthermore, there is a lack of data on utilities 
and lost income for caregivers of patients with SMA. As 
such, we did not include caregiver burden in the analyses 
using a modiied societal perspective.
Onasemnogene abeparvovec-xioi (Zolgensma) is 
another potential treatment option for the infantile-
onset SMA patients. [29] he evidence for Zolgensma 
in infantile-onset SMA is based on a single-armed study 
recruiting 12 patients, and there are no head to head tri-
als comparing Zolgensma with nusinersen. here are also 
diferences in study populations related to age at treat-
ment initiation and disease duration that limit our abil-
ity to adequately distinguish the net health beneit, and 
consequently cost-efectiveness, of Zolgensma versus 
nusinersen for infantile-onset SMA. Given these consid-
erations, we did not feel it was appropriate to include a 
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comparison of Zolgensma versus nusinersen in our anal-
ysis and have focused our manuscript on nusinersen in 
infantile-onset SMA patients.
Conclusions
his study represents the irst de novo cost-efectiveness 
model of infantile-onset SMA patients in the US. In our 
base-case analysis, nusinersen produces greater QALYs 
and LYs (3.24 and 7.64, respectively) compared with BSC 
(0.46 QALYs and 2.40 LYs), resulting in an incremen-
tal cost per QALY gained of approximately $1,112,000 
and an incremental cost per LY gained of $590,000 for 
nusinersen compared with BSC. Cost-efectiveness was 
dependent on the assumptions made about survival, 
costs, and utilities, and whether the motor function 
milestones were sustained over lifetime. At its current 
price, nusinersen does not meet traditional cost-efec-
tiveness thresholds in the US. Given the relatively short-
term efectiveness and utility data available, a registry 
to collect long-term data relating to eicacy and util-
ity within infantile-onset SMA patients on treatment 
is recommended to allow a more accurate estimate of 
cost-efectiveness.
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